Probably because "Biogen offered to buy Sage, its marketing partner on Zurzuvae, a pill to treat postpartum depression, for $469 million — less than the $569 million in cash that Sage has on hand as of September. The lowball offer is unlikely to be accepted, but Sage also has little leverage after a series of clinical failures last year wiped out its research pipeline and decimated its stock price."
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
1.3¢ |
Change
-0.001(3.85%) |
Mkt cap ! $89.60M | |||
| Open | High | Low | Value | Volume |
| 1.3¢ | 1.3¢ | 1.2¢ | $126.6K | 10.00M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 33 | 10606168 | 1.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.3¢ | 11548179 | 22 |
View Market Depth
| Last trade - 11.51am 30/06/2025 (20 minute delay) ? |
| IMU (ASX) Chart |